EW - Edwards Lifesciences Corporation (EW) Q1 2024 Earnings Call Transcript
2024-04-25 21:19:07 ET
Edwards Lifesciences Corporation (EW)
Q1 2024 Earnings Conference Call
April 25, 2024 05:00 PM ET
Company Participants
Mark Wilterding - SVP & IR
Bernard Zovighian - CEO
Scott Ullem - CFO
Daveen Chopra - Global Leader of TMTT
Larry Wood - Group President of TAVR and Surgical Structural Heart
Katie Szyman - Global Leader of Critical Care
Conference Call Participants
Robbie Marcus - JPMorgan
Travis Steed - Bank of America
Larry Biegelsen - Wells Fargo
Matt Taylor - Jefferies
Joanne Wuensch - Citi
Matt Miksic - Barclays
Shagun Singh - RBC Capital Markets
Chris Pasquale - Nephron Research
Philip Chickering - Deutsche Bank
Richard Newitter - Truist Securities
Danielle Antalffy - UBS
Joshua Jennings - TD Cowen
Presentation
Operator
Greetings, and welcome to the Edwards Lifesciences First Quarter 2024 Results. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Mark Wilterding, Senior Vice President, Investor Relations. Thank you, you may begin.
Mark Wilterding
Thanks a lot, Diego, and good afternoon, and thank you all for joining us. With me on today's call is our CEO, Bernard Zovighian, and our CFO, Scott Ullem. Also joining us for the Q&A portion of the call will be Larry Wood, our Global President of TAVR and Surgical Structural Heart; Daveen Chopra, our Global Leader of TMTT; Wayne Markowitz, our Global Leader of Surgical Structural Heart; and Katie Syzman, our Global Leader of Critical Care.
Just after the close of regular trading, Edwards Lifesciences released first quarter 2024 financial results. During today's call, management will discuss these results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections.
These statements include, but are not limited to, financial guidance and expectations for longer growth opportunities, regulatory approvals, clinical trials, litigation, reimbursement, competitive matters and foreign currency fluctuations. These statements speak only as of the date on which they were made, and Edwards does not undertake any obligation to update them after today.
Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important product safety information may be found in the press release, our 2023 annual reform on Form 10-K and Edwards' other SEC filings, all of which are available on the company's website at edwards.com.
Finally, unless otherwise noted, our commentary on sales growth refers to constant currency sales growth, which is defined in the quarterly press release issued earlier today. Reconciliations between GAAP and non-GAAP numbers mentioned during this call are also included in today's press release....
Edwards Lifesciences Corporation (EW) Q1 2024 Earnings Call Transcript